Company:  SAREPTA THERAPEUTICS, INC ... (SRPT)
Form Type:  8-K
Filing Date:  6/27/2018 
CIK:  0000873303 
Address:  215 FIRST STREET
SUITE 415
 
City, State, Zip:  CAMBRIDGE, Massachusetts 02142 
Telephone:  617-274-4000 
Fiscal Year:  12/31 
Last Trade
Last Trade: 
$122.22  
Change: 
-2.73 (-2.19%)  
Trade Time: 
02:43 PM EST  
Market Cap: 
$9.09B
Trade SRPT now with 

© 2019  
Description of Business
We are a commercial-stage biopharmaceutical company focused on helping patients through the discovery and development of unique RNA-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. Applying our proprietary, highly-differentiated and innovative technologies, and through collaborations with our strategic partners, we are developing potential therapeutic candidates for a broad range of diseases and disorders, including Duchenne muscular dystrophy ("DMD"), Limb-girdle muscular dystrophies ("LGMDs"), Mucopolysaccharidosis type IIIA ("MPS IIIA") and Pompe. Our first commercial product in the U.S., EXONDYS 51® (eteplirsen) Injection ("EXONDYS 51"), was granted accelerated approval by the FDA on September 19, 2016. EXONDYS 51 is indicated for the treatment of DMD in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.
Register and access this filing in:     
  FORM 8-K
    SECTION 5 CORPORATE GOVERNANCE
      Item 5.02. Departure of Directors or Certain Officers; ...
    SIGNATURES